Back

Long term outcome after septal reduction therapies in patients with hypertrophic cardiomyopathy: insights from the SHaRe registry

27 August 2023 (10:45 - 10:55)
Organised by: Logo
Congress Presentation Part of: Contemporary management of hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Niccolo' Maurizi

University Hospital of Lausanne, Lausanne (Switzerland)

5 More presentations in this session

Presentation thumbnail
Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeks
Doctor P. Garcia-Pavia (Majadahonda, ES)
Abstract Slides Video
Presentation thumbnail
Sacubitril/valsartan for treatment of symptomatic non-obstructive hypertrophic cardiomyopathy: a randomised, controlled, phase II clinical trial (SILICOFCM)
Doctor M. Tafelmeier (Regensburg, DE)
Abstract Slides Video
Presentation thumbnail
Efficacy of cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials
Ms N. Felix (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Outcomes in patients with hypertrophic cardiomyopathy developing left ventricular systolic dysfunction after septal reduction therapy
Miss D. Hiestand (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
The efficacy and safety of direct oral anticoagulants compared with vitamin K antagonist in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis
Miss S. Lyu (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Contemporary management of hypertrophic cardiomyopathy
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 10:45 CET
You may be interested in
thumbnail
Congress Session
Contemporary management of hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Outcomes in patients with hypertrophic cardiomyopathy developing left ventricular systolic dysfunction after septal reduction therapy
thumbnail
Congress Session
Septal reduction and myosin inhibitors: competing or complementary therapies?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources